A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Abstract Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.

Bibliographic Details
Main Authors: Keiko Yamaoka, Shuichi Nagashima, Nobukazu Okada, Nagisa Sawayama, Shinsuke Saito, Manabu Takahashi, Kenta Okada, Kazuhiro Endo, Masaru Koizumi, Hideki Sasanuma, Ken Ebihara, Atsuko Kasajima, Noriyoshi Fukushima, Naohiro Sata, Shun Ishibashi
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Clinical Case Reports
Subjects:
hypoglycemia
insulinoma
lanreotide
octreotide
somatostatin analog
Online Access:https://doi.org/10.1002/ccr3.4118

Internet

https://doi.org/10.1002/ccr3.4118

Similar Items